Generic placeholder image

Current Rheumatology Reviews

Editor-in-Chief

ISSN (Print): 1573-3971
ISSN (Online): 1875-6360

Research Article

Satisfaction and Adherence to Biological Treatment in Patients with Rheumatic Diseases

Author(s): Marwa Hammad* and Huny Bakry

Volume 18, Issue 3, 2022

Published on: 16 February, 2022

Page: [250 - 256] Pages: 7

DOI: 10.2174/1573397118666211230101451

Price: $65

conference banner
Abstract

Background: Autoimmune inflammatory rheumatic diseases have long been treated by conventional disease-modifying anti-rheumatic drugs. Biological therapy is a new era in the treatment of rheumatic diseases, but satisfaction and adherence to it is still not well tested.

Aims: To assess the satisfaction and adherence to biological treatment among patients with autoimmune inflammatory rheumatic diseases.

Methods: A cross sectional study was conducted among 56 patients suffering from inflammatory rheumatic diseases using Morisky 8 questionnaire and Treatment Satisfaction Questionnaire for Medication (TSQM) over a period of one month.

Results: About 76.8 % of the patients had medium adherence and the underlying cause of missing doses was the unavailability of the drugs. The mean satisfaction with biological treatment was 62.7±6.9. Patients who did not receive formal education had significantly higher satisfaction with the biological treatment than others 64.94±5.01 at a P value 0.04 (<0.05).

Conclusion: Patients with inflammatory rheumatic diseases in our study showed medium adherence and satisfaction. Authorities in the medical field are providing great help to these patients in need of biological therapy, but ensuring the availability of all doses of the biological treatment regimen is still necessary. Patient, family and nurse education programs are also necessary to maximize adherence and satisfaction.

Keywords: Satisfaction, adherence, biological, rheumatic, therapy, disease.

[1]
Huang JC, Qian BP, Qiu Y, et al. Quality of life and correlation with clinical and radiographic variables in patients with ankylosing spondylitis: A retrospective case series study. BMC Musculoskelet Disord 2017; 18(1): 352.
[http://dx.doi.org/10.1186/s12891-017-1711-1] [PMID: 28810915]
[2]
Ward MM, Deodhar A, Akl EA, et al. American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheumatol 2016; 68(2): 282-98.
[http://dx.doi.org/10.1002/art.39298] [PMID: 26401991]
[3]
Singh JA, Furst DE, Bharat A, et al. 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012; 64(5): 625-39.
[http://dx.doi.org/10.1002/acr.21641] [PMID: 22473917]
[4]
Dobbels F, Van Damme-Lombaert R, Vanhaecke J, De Geest S. Growing pains: Non-adherence with the immunosuppressive regimen in adolescent transplant recipients. Pediatr Transplant 2005; 9(3): 381-90.
[http://dx.doi.org/10.1111/j.1399-3046.2005.00356.x]
[5]
Krueger KP, Felkey BG, Berger BA. Improving adherence and persistence: A review and assessment of interventions and description of steps toward a national adherence initiative. J Am Pharm Assoc (Wash DC) 2003; 43(6): 668-78.
[http://dx.doi.org/10.1331/154434503322642598] [PMID: 14717263]
[6]
Blum MA, Koo D, Doshi JA. Measurement and rates of persistence with and adherence to biologics for rheumatoid arthritis: A systematic review. Clin Ther 2011; 33(7): 901-13.
[http://dx.doi.org/10.1016/j.clinthera.2011.06.001] [PMID: 21715007]
[7]
Hawthorne AB, Rubin G, Ghosh S. Review article: Medication non-adherence in ulcerative colitis--strategies to improve adherence with mesalazine and other maintenance therapies. Aliment Pharmacol Ther 2008; 27(12): 1157-66.
[http://dx.doi.org/10.1111/j.1365-2036.2008.03698.x] [PMID: 18384664]
[8]
Calvo-Alén J, Marras Fernandez-Cid C, Monteagudo I, et al. THU0137 non-adherence to subcutaneous biological therapy in patients with rheumatoid arthritis. Ann Rheum Dis 2016; 75: 230-1.
[http://dx.doi.org/10.1136/annrheumdis-2016-eular.3473]
[9]
Joplin S, Zwan R, Joshua F, Wong P. Medication adherence in patients with rheumatoid arthritis: The effect of patient education, health literacy, and musculoskeletal ultrasound. BioMed Res Int 2015; 2015: 150658.
[10]
Lindström U, Olofsson T, Wedrén S, Qirjazo I, Askling J. Biological treatment of ankylosing spondylitis: A nationwide study of treatment trajectories on a patient level in clinical practice. Arthritis Res Ther 2019; 21(1): 128.
[http://dx.doi.org/10.1186/s13075-019-1908-9] [PMID: 31138285]
[11]
Bluett J, Morgan C, Thurston L, et al. BRAGGSS. Impact of inadequate adherence on response to subcutaneously administered anti-tumour necrosis factor drugs: results from the biologics in rheumatoid arthritis genetics and genomics study syndicate cohort. Rheumatology (Oxford) 2015; 54(3): 494-9.
[http://dx.doi.org/10.1093/rheumatology/keu358] [PMID: 25213131]
[12]
Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986; 24(1): 67-74.
[http://dx.doi.org/10.1097/00005650-198601000-00007] [PMID: 3945130]
[13]
Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens (Greenwich) 2008; 10(5): 348-54.
[http://dx.doi.org/10.1111/j.1751-7176.2008.07572.x] [PMID: 18453793]
[14]
Atkinson MJ, Kumar R, Cappelleri JC, Hass SL. Hierarchical construct validity of the Treatment Satisfaction Questionnaire for Medication (TSQM version II) among outpatient pharmacy consumers. Value Health 2005; 8(Suppl. 1): S9-S24.
[http://dx.doi.org/10.1111/j.1524-4733.2005.00066.x] [PMID: 16336491]
[15]
Atkinson MJ, Sinha A, Hass SL, et al. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes 2004; 2: 12.
[http://dx.doi.org/10.1186/1477-7525-2-12] [PMID: 14987333]
[16]
Awadallah H. Treatment satisfaction, its relation to beliefs about medicine, quality of life and adherence among diabetic patients Msc thesis, Al Quds University, Jerusalem 2019.
[17]
Anghel LA, Farcaş AM, Oprean RN. Medication adherence and persistence in patients with autoimmune rheumatic diseases: A narrative review. Patient Prefer Adherence 2018; 12: 1151-66.
[http://dx.doi.org/10.2147/PPA.S165101] [PMID: 30013327]
[18]
Waimann CA, Marengo MF, de Achaval S, et al. Electronic monitoring of oral therapies in ethnically diverse and economically disadvantaged patients with rheumatoid arthritis: consequences of low adherence. Arthritis Rheum 2013; 65(6): 1421-9.
[http://dx.doi.org/10.1002/art.37917] [PMID: 23728826]
[19]
Parkoohi PI. Satisfaction with chronic pain treatment. Anesth Pain Med 2015; 5(4): e23528.
[20]
Martin Du Pan S, Dehler S, Ciurea A, et al. Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis & rheumatism. Arthritis Care Res 2009; 61(5): 560-8.
[http://dx.doi.org/10.1002/art.24463]
[21]
Allen PB, Lindsay H, Tham TC. How do patients with inflammatory bowel disease want their biological therapy administered? BMC Gastroenterol 2010; 10: 1.
[http://dx.doi.org/10.1186/1471-230X-10-1] [PMID: 20064220]
[22]
De Vera MA, Mailman J, Galo JS. Economics of non-adherence to biologic therapies in rheumatoid arthritis. Curr Rheumatol Rep 2014; 16(11): 460.
[http://dx.doi.org/10.1007/s11926-014-0460-5] [PMID: 25227187]
[23]
Heidari P, Cross W, Crawford K. Do out-of-pocket costs affect medication adherence in adults with rheumatoid arthritis? A systematic review. Semin Arthritis Rheum 2018; 48(1): 12-21.
[http://dx.doi.org/10.1016/j.semarthrit.2017.12.010] [PMID: 29496225]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy